Bringing Groundbreaking Treatments to Patients with Psychiatric and Neurodegenerative Diseases
Unleashing unique properties and biological effects of Noble gases for treatment of PTSD, Autism, Dementia
Combining revolutionary portable inhalation device with a safe therapeutic
Accelerated pathway of clinical development
Nobilis Therapeutics is a clinical stage biotechnology company developing proprietary inhalation-based therapeutics using controlled self-administration of inert gases to address unmet medical need in the treatment of psychiatric and neurodegenerative diseases.
By leveraging data on more than 2500 patients successfully treated for conditions ranging from panic disorder to autoimmune diseases, Nobilis has coupled its patent pending gas mixtures with a proprietary inhalational device to offer reproducible, standardized, and controlled patient exposure. The Company is currently advancing its technologies into human clinical trials.
News Feed
- Nobilis Therapeutics’ treatment approach gets a favorable review from the Journal of Experimental Pharmacology June 14, 2021
- Nobilis Therapeutics to Participate in BIO Digital Conference, June 10-11 and 14-18. June 8, 2021
- Nobilis Therapeutics Presentation at CapCon Investor Conference December 8, 2020
- Nobilis Therapeutics to Present at CapCon 2020 Venture Conference November 4, 2020
- Nobilis Therapeutics is Granted a US Patent for its Invention “THERAPEUTIC IMMUNE MODULATION USING NOBLE GAS COMPOSITIONS” that covers its use in Autism Spectrum Disorder October 22, 2020
- Nobilis Therapeutics Announces FDA Clearance of IND to Commence Phase 2b Trial of NBTX-001 Inhaler for Treatment of Panic Disorder July 22, 2020
- Nobilis Therapeutics Announces IND Filing for a Phase 2b Clinical Trial of NBTX-001 Drug/Device Combination for Treatment of Panic Disorder June 23, 2020
- Nobilis Therapeutics Has Won NIH’s National Institutes of Drug Abuse “$100,000 For Start a SUD Startup 2020” Spring Challenge June 22, 2020
- Nobilis Therapeutics Receives a Notice of Allowance for its European Patent Application “Therapeutic Immune Modulation Using Noble Gas Compositions” May 2, 2020
- Imminent Mental Health Crisis in America April 10, 2020
- Nobilis Therapeutics Supports Grant Application to IOCDF for an Investigator-initiated Clinical Trial of NBTX-001 in Patients with Obsessive-Compulsive Syndrome February 28, 2020
- Nobilis Therapeutics to attend 38th Annual J.P. MORGAN Healthcare Conference on January 13-16, 2020 January 3, 2020
- NBTX-001 is profiled in “Pharmacology and Therapeutics Journal” as one promising novel treatment candidates for anxiety-related disorders December 25, 2019
- Nobilis Therapeutics Announces FDA Clearance of IND to Commence Phase 2b Trial of NBTX-001 Inhaler for Treatment of Posttraumatic Stress Disorder December 6, 2019
- Nobilis Therapeutics’ NBTX-001 Showed Beneficial Effects in an Animal Model of Autism December 3, 2019
- US Patent is Granted for Nobilis Therapeutics Invention On the Use of Noble Gases to Treat Complications of Pregnancy November 26, 2019
- Nobilis Therapeutics published an article “Combining Xenon Inhalation With Trauma Memory Reactivation to Reduce Symptoms of Posttraumatic Stress Disorder: Case Report, Justification of Approach, and Review of the Literature” in Primary Care Companion For CNS Disorders September 20, 2019
- US Patent Granted for Nobilis Therapeutics Invention Covering the Use of Xenon in ALS August 27, 2019
- Nobilis Therapeutics will present two abstracts at the 19th WPA World Congress of Psychiatry July 17, 2019
- Nobilis Therapeutics Enters into Collaboration with The Linde Group to Support Its Clinical Research Program to Study a drug/device combination for Treatment of PTSD and Other CNS Disorders. January 10, 2019
Twitter Feed
Nobilis Therapeutics @NobilisTx
When coupled with trauma memory reactivation propranolol is, largely, no more effective than placebo. Interestingly, the placebo group showed positive results. Our 2b PTSD trial had been designed very similarly, but with a much more potent drug. https://t.co/sujs07qtek
Nobilis Therapeutics @NobilisTx
55% of COVID-19 survivors develop at least one psychiatric disorder (28% - PTSD, 31% - depression, 42% - anxiety, 20% - OCD, 40% - insomnia) https://t.co/i7PfEEzW0I